FDA Approves Leucovorin for Rare CFD-FOLR1 Disorder; GSK Holds NDA
The FDA approved the expanded use of leucovorin calcium to treat cerebral folate deficiency in adult and pediatric patients with a confirmed FOLR1 gene variant, marking the first available therapy for this rare neurological disorder. GSK, as the New Drug Application holder, facilitated updated labeling for generic versions.
1. FDA Approval Details
The FDA has expanded the indication for leucovorin calcium tablets to include cerebral folate deficiency in adult and pediatric patients with a confirmed FOLR1 gene variant (CFD-FOLR1). This marks the first targeted treatment for a genetic disorder characterized by developmental delays, movement disorders and seizures due to impaired folate transport into the brain.
2. GSK’s Role and Labeling Update
GSK plc holds the New Drug Application for Wellcovorin and collaborated with the FDA to update prescribing information for safe use in CFD-FOLR1 patients. Although GSK no longer manufactures the drug, generics will now carry the updated labeling reflecting this new neurological indication.
3. Market Implications and Outlook
Cerebral folate deficiency affects a small, ultra-rare patient population, suggesting limited commercial revenue but significant clinical impact for affected families. The approval may bolster generic manufacturers’ market share and enhance GSK’s reputation as an NDA holder for orphan therapies.